Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Epigenetic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for JMJD1C drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | JMJD1C Recombinant Protein (Active Domain) High purity (>95%), Endotoxin Controlled, Sequence Verified. Optimized for enzymatic and binding assays. |
View JMJD1C Products |
| Gene Delivery | JMJD1C Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target validation. |
View JMJD1C Products |
| Benchmark Ab | Anti-JMJD1C Recombinant Antibody High-affinity sequence-verified positive control for Western Blot, IP, and ChIP. |
View JMJD1C Products |
| Validator | JMJD1C siRNA Set Target-specific knockdown verification to confirm phenotype-to-target linkage. |
View JMJD1C Products |
| Related Target A | JMJD1A (KDM3A) High-homology subfamily member required for selectivity and counter-screening assays. |
View JMJD1A Products |
| Related Target B | AR (Androgen Receptor) Critical downstream signaling partner; JMJD1C acts as a co-activator of AR in prostate cancer. |
View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Off-Target Screening | Human JMJD1A, JMJD1B, and JMJD1C catalytic domain proteins strictly verified by Mass Spectrometry. |
| Assay Interference from Impurities | Ultra-low endotoxin control and high purity (>95% by SDS-PAGE) to ensure robust enzymatic screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant controls included. |
| False Positives in Phenotypic Screens | Sequence-specific validated siRNA sets for orthologous gene knockdown verification. |
Live JMJD1C R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for JMJD1C therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum epigenetic inhibitors to highly selective small molecule inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation epigenetic therapies reach the clinic, the next wave of R&D is targeting JMJD1C's specific role in acute myeloid leukemia (AML) with MLL rearrangements and castration-resistant prostate cancer (CRPC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | AML, T-ALL, Solid Tumors | Enzymatic Activity & Selectivity Assay (Need highly pure catalytic domains) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Prostate Cancer (CRPC) | Ternary Complex Formation Assay (Need stable, sequence-verified full-length or domain proteins) |
| Combination Therapies | Oncology Therapeutics Developers | Hormone-Refractory Cancers | Synergy Validation (Need siRNA knockdown combined with small molecule treatments) |